PEG loxenatide

Drug Profile

PEG loxenatide

Alternative Names: PEX168; Polyethylene glycol loxenatide

Latest Information Update: 06 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Jiangsu Hansoh Pharmaceutical; Jiangsu Hengrui Medicine Co.
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Polyethylene glycols
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Type 2 diabetes mellitus

Most Recent Events

  • 06 Sep 2017 PEG loxenatide is still in phase III trials for Type 2 diabetes mellitus in China
  • 15 Dec 2016 Biomarkers information updated
  • 12 Jul 2016 Jiangsu Hansoh Pharmaceutical completes a phase I drug interaction trial (In volunteers) in China (NCT02461914)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top